World Hemophilia Day: Sanofi Genzyme donation impacts patients across the globe

On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding episodes that can cause pain, irreversible joint damage, and life-threatening hemorrhages.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Related Links:

We present a case of a 68-year-old Hispanic female with a history of factor VII deficiency who presented with shortness of breath, chest pain, and palpitations and was found to have pulmonary embolism. Our patient did not have any of the above-mentioned thrombotic risk factors. Our case and review of the literature show that factor VII deficiency does not provide protection against thrombosis. PMID: 31590173 [PubMed - as supplied by publisher]
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
Authors: Park N, Jang JS, Cha JH Abstract Peptic ulcer disease is the most common cause of acute gastrointestinal bleeding, followed by variceal bleeding, Mallory-Weiss syndrome, and malignancy. On the contrary, acquired hemophilia A is a very rare hemorrhagic disease, which usually manifests with musculocutaneous bleeding, caused by autoantibodies against coagulation factor VIII. A 78-year-old man presented to the Emergency Department with melena. Dieulafoy's lesions were observed on esophagogastroduodenoscopy, and endoscopic cauterization was performed. However, the patient complained of back pain and symptoms in...
Source: Clinical Endoscopy - Category: Gastroenterology Tags: Clin Endosc Source Type: research
Cochrane is made up of  13,000 members and over 50,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Cochrane is an incredible community of people who all play their part in improving health and healthcare globally. We believe that by putting trusted evidence at the heart of health decisions we can achieve a world of improved health for all.  Many  of our contributors are young people working with Cochrane ...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
This study shows that joint aspiration under hemostatic cover and in strictly aseptic conditions is a well-tolerated technique that makes the recovery of acute hemarthrosis of hemophilic patients faster.
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: ORIGINAL ARTICLES Source Type: research
Conclusions: Our findings suggest that systemic vascular collagen turn-over products may be novel biomarker candidates to identify patients at high risk for joint bleeding and to diagnose acute hemarthrosis. Hemarthrosis in hemophilia is associated with pronounced synovial vascular remodeling. Cleavage products of type IV collagen, but not of any other collagen, were systemically elevated in PWH and distinguished bleeding from non-bleeding painful episodes. Type IV collagen is found exclusively in basement membranes and in the case of joint bleeding, the presumed source of these turnover markers is newly formed synovial bl...
Source: Blood - Category: Hematology Authors: Tags: 322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Advances in Treatment and Physiology Source Type: research
ConclusionsAlmost all patients in HAVEN 3 and all patients in HAVEN 4 preferred emicizumab to their prior treatment. These results likely reflect the high efficacy and lower treatment burden previously reported. Such strong preference will be important for individuals currently receiving either episodic or prophylactic treatment when considering emicizumab prophylaxis in the future and may be associated with improved adherence, a substantial clinical obstacle with FVIII or BPAs.DisclosuresJimenez-Yuste: Roche: Consultancy, Research Funding; Shire: Consultancy, Research Funding; Bayer: Consultancy, Research Funding; Sobi: C...
Source: Blood - Category: Hematology Authors: Tags: 322. Disorders of Coagulation or Fibrinolysis: Poster I Source Type: research
Conclusions:This study provides an estimate of the burden of inhibitors in persons with severe hemophilia A in the US, representing approximately 52.9% of all severe hemophilia A patients treated in the USHTCN (CDC, unpublished data). History of an inhibitor reduced patient productivity and increased ED and hospital utilization. Future efforts will focus on a longitudinal analysis of this cohort to better understand the natural history and outcome of inhibitors and their impact on patient quality of life and health care utilization.Acknowledgements:This study was performed with the advice of the Community Counts Inhibitor ...
Source: Blood - Category: Hematology Authors: Tags: 322. Disorders of Coagulation or Fibrinolysis: Poster II Source Type: research
Conclusions: The model suggests that prophylaxis treatment of HA with emicizumab can result in a lower number of bleeding events as well as delayed onset of arthropathy and inhibitor development. Findings indicate that prophylaxis with emicizumab leads to better patient outcomes and has a lower financial impact from the US societal perspective.DisclosuresMahajerin: Genentech Inc.: Consultancy. Zhou: Analysis Group, Inc.: Employment; Celgene Corporation: Research Funding. Raimundo: Genentech Inc: Employment, Other: Ownership interests PLC. Patel: Genentech Inc: Employment. Han: Analysis Group Inc.: Research Funding. Ji: Ana...
Source: Blood - Category: Hematology Authors: Tags: 901. Health Services Research-Non-Malignant Conditions: Poster II Source Type: research
This study aims to describe interventions for pain management in PwHA in the US.Methods: This retrospective cross-sectional analysis identified PwHA between 2006-2015 using data from Truven Health Analytics MarketScan® Commercial Database. PwHA were identified using a previously validated claims-based algorithm with high sensitivity and specificity (Lyons et al. Value Health 2018). PwHA with pain were identified if they had at least one medical claim for pain as identified by the International Classification of Diseases, Ninth and Tenth Revision codes (ICD-9 &ICD-10). Pharmacologic treatment alternatives, including...
Source: Blood - Category: Hematology Authors: Tags: 901. Health Services Research-Non-Malignant Conditions: Poster I Source Type: research
Introduction: Recombinant Factors VIII Fc (rFVIIIFc) and IX Fc (rFIXFc) fusion proteins are extended half-life (EHL) factor products approved in Canada in 2014 and became available through the Canadian Blood Services in January 2016. Real-world product utilization and clinician practice patterns in EHL prescription are unknown.Objectives: This is a prospective Canadian multi-centre observational study to describe product utilization, clinical and patient-reported outcomes (PROs) in patients pre- and post-switch to rFVIIIFc/ rFIXFc products compared to those who remained on standard half-life (SHL) products. The primary out...
Source: Blood - Category: Hematology Authors: Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster III Source Type: research
More News: Bleeding | Genetics | Haemophilia | Hemophilia | Pain | Pharmaceuticals